- Home
- NODK vs ZNTL Comparison
NODK vs ZNTL Comparison
Compare NODK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ZNTL
- Stock Information
- Founded
- NODK 1946
- ZNTL 2014
- Country
- NODK United States
- ZNTL United States
- Employees
- NODK N/A
- ZNTL N/A
- Industry
- NODK Property-Casualty Insurers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- ZNTL Health Care
- Exchange
- NODK Nasdaq
- ZNTL Nasdaq
- Market Cap
- NODK 323.2M
- ZNTL 238.2M
- IPO Year
- NODK 2017
- ZNTL 2020
- Fundamental
- Price
- NODK $15.55
- ZNTL $3.12
- Analyst Decision
- NODK
- ZNTL Buy
- Analyst Count
- NODK 0
- ZNTL 7
- Target Price
- NODK N/A
- ZNTL $10.86
- AVG Volume (30 Days)
- NODK 20.0K
- ZNTL 1.2M
- Earning Date
- NODK 11-05-2024
- ZNTL 11-04-2024
- Dividend Yield
- NODK N/A
- ZNTL N/A
- EPS Growth
- NODK N/A
- ZNTL N/A
- EPS
- NODK N/A
- ZNTL N/A
- Revenue
- NODK $380,700,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- NODK N/A
- ZNTL N/A
- Revenue Next Year
- NODK N/A
- ZNTL N/A
- P/E Ratio
- NODK N/A
- ZNTL N/A
- Revenue Growth
- NODK 15.43
- ZNTL N/A
- 52 Week Low
- NODK $12.02
- ZNTL $2.83
- 52 Week High
- NODK $16.55
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- NODK 53.74
- ZNTL 44.34
- Support Level
- NODK $15.07
- ZNTL $2.92
- Resistance Level
- NODK $15.86
- ZNTL $3.23
- Average True Range (ATR)
- NODK 0.31
- ZNTL 0.17
- MACD
- NODK 0.00
- ZNTL 0.00
- Stochastic Oscillator
- NODK 63.53
- ZNTL 38.33
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.